# Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

> **NCT05710692** · PHASE2,PHASE3 · RECRUITING · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 16 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** PRX-102 1 mg/kg every 2 weeks
- **DRUG:** PRX-102 2 mg/kg every 4 weeks

## Key facts

- **NCT ID:** NCT05710692
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2027-10
- **Final completion:** 2029-08
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05710692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05710692, "Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05710692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*